The Pgp3 subunit vaccine elicits immune protection against Chlamydia trachomatis
infection, but additional adjuvants are still required to enhance its immunoprotective efficacy …

Urogenital tract infections with Chlamydia trachomatis have frequently been detected among
patients diagnosed with sexually transmitted infections, and such infections lead to …

Considering the shortcomings in current chlamydia infection control strategies, a major
challenge in curtailing infection is the implementation of an effective vaccine. The immune …

Previously we reported that recombinant Chlamydia muridarum macrophage infectivity
potentiator (MIP) provided partial protection against C. muridarum genital tract infection in …

Urogenital tract infection with Chlamydia trachomatis is a leading cause of sexually
transmitted infections. There is currently no commercially available vaccine against C …

Chlamydia psittaci is the pathogen of psittacosis, and it has emerged as a significant public
health threat. Because most infections are easily overlooked, a vaccine is recognized as the …

Efficacious vaccines are needed to control genital chlamydial diseases in humans and the
veterinary industry. We previously reported a C. abortus (Cab) vaccine comprising …

Chlamydia trachomatis pgp3 DNA immunized (no. 300) and non-immunized (no. 300)
C3H/HeN mice were infected by vaginal inoculation with infectious C. trachomatis serotype …

The control of the worldwide spread of sexually transmitted Chlamydia trachomatis (Ct)
infection urgently demands the development of a preventive vaccine. In this work, we …

We evaluated the immunogenicity and efficacy of a candidate vaccine comprising the major
outer membrane protein (MOMP) multi-epitope of Chlamydia trachomatis. A short gene of …